CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Moderna (MRNA) a catalyst driven idea at Morgan Stanley
January 6, 2023 12:17 PM ESTMorgan Stanley analyst Matthew Harrison labeled Moderna (NASDAQ: MRNA) a Catalyst Driven Idea in a note Friday, maintaining an Equal-Weight rating and $209 price target on the stock.
The analyst told investors the firm expects Moderna's first interim analysis from its Ph3 RSV vaccine study in the near term.
"We believe efficacy and... More
Morgan Stanley Calls Moderna (MRNA) a Catalyst Driven Idea
January 5, 2023 4:09 PM ESTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $209.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "We expect the first interim analysis from Moderna's Ph3 RSV vaccine study in the near-term. We believe efficacy and safety in-between... More
